Hepatocellular carcinoma is one of the most common malignant tumors, with approximately 780,000 cases worldwide each year. New treatment technologies and strategies are urgently needed to improve the prognosis of these patients. Recurrence and metastasis are the primary factors affecting the lives of HCC patients. For HCC patients complicated by inferior vena cava tumor thrombus, treatment options are limited and the overall prognosis is poor.Even with surgical resection, the median overall survival is only 17.8 months. (2).For patients who received other local or systemic therapies, median overall survival was 5.9 to 15.4 months (2-4).
exist May 2015Department of Interventional Oncology, Yanji Hospital Shanghai In collaboration with CARsgen Therapeutics, the first clinical study of CAR T cell therapy targeting the GPC3 (Glypican-3) protein in advanced hepatocellular carcinoma was initiated. (Part of the data for this study was published in clinical cancer research. 2020(5)). At the time of enrollment, two patients had developed inferior vena cava tumor thrombus, and one of them also had retroperitoneal lymph node metastasis, a particularly poor prognostic factor. However, both patients remained tumor-free during long-term follow-up after receiving combined local and CAR T-cell therapy. Recently, two patients returned to Renji Hospital for review and it was confirmed that the tumors had not recurred. Researchers at Renji Hospital held a brief celebration with the two patients.
Patient 1 was diagnosed with liver cancer and underwent two rounds of interventional therapy and one round of microwave ablation. However, his condition rapidly deteriorated and he developed inferior vena cava thrombosis. After local treatment (microwave ablation and gamma knife) for intrahepatic recurrent tumor and inferior vena cava tumor thrombus, the patient participated in a CAR-GPC3 T cell clinical trial. Six months later, the tumor biomarker AFP returned to normal, and imaging showed no obvious active tumor. To date, the patient has remained tumor-free for more than 8 years (July 2015 arrive August 2023). Patient 2 developed intrahepatic tumor recurrence after liver cancer resection. Despite multiple intensive TACE and microwave ablation treatments, the tumor could not be effectively controlled. Multiple recurrences (more than 6 lesions) occurred in the liver, as well as retroperitoneal lymph node metastasis and inferior vena cava tumor thrombus. Through local treatment (microwave ablation, gamma knife) targeting intrahepatic tumors, inferior vena cava tumor thrombus, peritoneal lymph node metastasis, etc., combined with CAR T cell therapy, the patient has achieved disease-free survival for more than 7 years.July 2016 arrive August 2023). At the same time, the patient reported fever, fatigue, transient leukopenia, thrombocytopenia, and grade 1 cytokine release syndrome during CAR-GPC3 T cell infusion.
During the entire follow-up period, two patients received only oral anti-HBV drugs and no other cancer treatments.
professor BuzhaiThe principal investigator of the study and director of the Interventional Oncology Department of Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine said, “The treatment of advanced hepatocellular carcinoma has always been a big challenge, especially for patients with inferior vein venous tumor thrombus, which has a poor prognosis. Factors, in this case report, two patients achieved long-term disease-free survival through a combination of local therapy and GPC3-targeted CAR T-cell therapy, bringing new hope to patients with advanced hepatocellular carcinoma. After tremendous efforts by scientists efforts, the development of CAR T cell therapy for solid tumors still faces various challenges, such as the inherent physical and immune barriers of solid tumors, tumor cell heterogeneity, antigen specificity, and potential risks associated with CAR T cell therapy.”
Dr. Li Zonghai, founder, chairman, CEO and chief scientific officer of CARsgen, added: “With the mission of making cancer curable, CARsgen has been developing various innovative strategies to treat solid tumors using CAR-T cells: For example, we For the first time, a combination of a small molecule drug and CAR-GPC3 T cell therapy was reported to achieve sustained complete remission in subjects with advanced hepatocellular carcinoma. (6). This time, the study reported that two patients with advanced hepatocellular carcinoma achieved disease-free survival for more than seven years after receiving local therapy and targeted CAR-GPC3 T cell infusion, demonstrating the potential of CAR T cell therapy through innovation. therapeutic strategies to cure solid tumors. “
About Keji Gene Therapy Holdings Limited
CARsgen is a biopharmaceutical company with operations in China and the United States, focused on innovative CAR T cell therapies for the treatment of hematological malignancies and solid tumors. CARsgen has established a comprehensive CAR T cell research and development platform, covering target discovery, innovative CAR T cell development, clinical trials and commercial scale production. CARsgen has internally developed new technologies and a pipeline of products with global rights to address key challenges in CAR T-cell therapy, such as improving safety, enhancing efficacy in treating solid tumors, and reducing treatment costs. CARsgen’s vision is to become a global biopharmaceutical leader, bringing innovative and differentiated cell therapies to cancer patients around the world, making cancer curable.
forward-looking statements
All statements in this press release that are not historical facts or that do not relate to current facts or current conditions are forward-looking statements. Such forward-looking statements express the Group’s current views, forecasts, beliefs and expectations with respect to future events as of the date of this press release. Such forward-looking statements are based on a number of assumptions and factors beyond the control of the Group. Accordingly, they are subject to significant risks and uncertainties, actual events or results may differ materially from these forward-looking statements, and the forward-looking events discussed in this release may not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading “Key Risks and Uncertainties” in our most recent annual and interim reports and other announcements and reports on our corporate website at https://www. Uncertainty. carsgen.com. We make no representation or warranty as to the achievement or reasonableness of any forecasts, targets, estimates or forecasts contained in this press release, and no reliance should be placed on them.
refer to
- Shi Y, et al. arrive. Cancer Community (London). July 21, 2023.
- Kunito T et al. arrive. Hepatology. August 2017; 66(2):510-517.
- Lu Jie et al. arrive. BMC cancer. 2019 July 5;19(1):668.
- Rim CH et al. arrive. International Journal of Radiobiology. June 2020; 96(6):759-766.
- Shi DH, et al. clinical cancer research. Chapter 2020; 26(15):3979-3989.
- Sun Hong, wait. arrive. Frontier immunity. 2022 Aug 17;13:963031.
Contact CARsgen
For more information, please visit https://www.carsgen.com/
Public Relations: PR@carsgen.com
Investor Relations: IR@carsgen.com
SOURCE CARsgen Therapeutics
Also from this source
